A carregar...
The complex relationship between MITF and the immune system: a Melanoma ImmunoTherapy (response) Factor?
The clinical benefit of immune checkpoint inhibitory therapy (ICT) in advanced melanomas is limited by primary and acquired resistance. The molecular determinants of the resistance have been extensively studied, but these discoveries have not yet been translated into therapeutic benefits. As such, a...
Na minha lista:
| Publicado no: | Mol Cancer |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7718690/ https://ncbi.nlm.nih.gov/pubmed/33276788 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-020-01290-7 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|